Does the media favor ALEC or AVTX?

In the previous week, Avalo Therapeutics had 2 more articles in the media than Alector. MarketBeat recorded 4 mentions for Avalo Therapeutics and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat Avalo Therapeutics' score of 0.29 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALEC or IMMX more profitable?

Immix Biopharma has a net margin of 0.00% compared to Alector's net margin of -850.13%. Immix Biopharma's return on equity of -38.44% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% Immix Biopharma N/A -38.44% -34.72%

Does the media favor ALEC or IMMX?

In the previous week, Immix Biopharma had 22 more articles in the media than Alector. MarketBeat recorded 24 mentions for Immix Biopharma and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat Immix Biopharma's score of 0.38 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALEC or LXRX?

In the previous week, Lexicon Pharmaceuticals had 17 more articles in the media than Alector. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALEC or FDMT?

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Alector. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat 4D Molecular Therapeutics' score of 0.47 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ALEC or GERN?

Geron has higher revenue and earnings than Alector. Geron is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 9.60 -$142.93M -$1.10 N/A Geron $183.88M 4.19 -$83.50M -$0.11 N/A

Is ALEC or GERN more profitable?

Geron has a net margin of -34.17% compared to Alector's net margin of -850.13%. Geron's return on equity of -24.48% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% Geron -34.17% -24.48% -10.30%

Does the media favor ALEC or GERN?

In the previous week, Alector had 1 more articles in the media than Geron. MarketBeat recorded 2 mentions for Alector and 1 mentions for Geron. Alector's average media sentiment score of 0.67 beat Geron's score of 0.51 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alector (ALEC) Competitors

$1.81 -0.05 (-2.69%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.82 +0.01 (+0.50%)

As of 10/2/2026 07:30 PM Eastern

Compare

ALEC vs. AVTX, IMMX, LXRX, FDMT, and GERN

Should you buy Alector stock or one of its competitors? Alector's main competitors and comparable companies include Avalo Therapeutics (AVTX), Immix Biopharma (IMMX), Lexicon Pharmaceuticals (LXRX), 4D Molecular Therapeutics (FDMT), and Geron (GERN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alector compare to Avalo Therapeutics?

Alector (NASDAQ:ALEC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Avalo Therapeutics has a net margin of 0.00% compared to Alector's net margin of -850.13%. Avalo Therapeutics' return on equity of -58.03% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Alector currently has a consensus target price of $3.63, suggesting a potential upside of 100.28%. Avalo Therapeutics has a consensus target price of $45.10, suggesting a potential upside of 200.87%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Avalo Therapeutics has lower revenue, but higher earnings than Alector. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.60	-$142.93M	-$1.10	N/A
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A

85.8% of Alector shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alector has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Avalo Therapeutics had 2 more articles in the media than Alector. MarketBeat recorded 4 mentions for Avalo Therapeutics and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat Avalo Therapeutics' score of 0.29 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalo Therapeutics beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Immix Biopharma?

Alector (NASDAQ:ALEC) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Alector has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Alector currently has a consensus target price of $3.63, suggesting a potential upside of 100.28%. Immix Biopharma has a consensus target price of $24.14, suggesting a potential upside of 149.41%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Immix Biopharma has a net margin of 0.00% compared to Alector's net margin of -850.13%. Immix Biopharma's return on equity of -38.44% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Immix Biopharma	N/A	-38.44%	-34.72%

85.8% of Alector shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immix Biopharma has lower revenue, but higher earnings than Alector. Immix Biopharma is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.60	-$142.93M	-$1.10	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

In the previous week, Immix Biopharma had 22 more articles in the media than Alector. MarketBeat recorded 24 mentions for Immix Biopharma and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat Immix Biopharma's score of 0.38 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immix Biopharma beats Alector on 10 of the 15 factors compared between the two stocks.

How does Alector compare to Lexicon Pharmaceuticals?

Alector (NASDAQ:ALEC) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Lexicon Pharmaceuticals has higher revenue and earnings than Alector. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.60	-$142.93M	-$1.10	N/A
Lexicon Pharmaceuticals	$49.80M	16.26	-$50.34M	-$0.15	N/A

Alector has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

85.8% of Alector shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alector currently has a consensus price target of $3.63, indicating a potential upside of 100.28%. Lexicon Pharmaceuticals has a consensus price target of $5.70, indicating a potential upside of 213.19%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Lexicon Pharmaceuticals had 17 more articles in the media than Alector. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat Lexicon Pharmaceuticals' score of 0.34 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexicon Pharmaceuticals has a net margin of -147.38% compared to Alector's net margin of -850.13%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Summary

Lexicon Pharmaceuticals beats Alector on 12 of the 15 factors compared between the two stocks.

How does Alector compare to 4D Molecular Therapeutics?

Alector (NASDAQ:ALEC) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Alector has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market.

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Alector. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 2 mentions for Alector. Alector's average media sentiment score of 0.67 beat 4D Molecular Therapeutics' score of 0.47 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.8% of Alector shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alector presently has a consensus price target of $3.63, indicating a potential upside of 100.28%. 4D Molecular Therapeutics has a consensus price target of $29.00, indicating a potential upside of 112.14%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

4D Molecular Therapeutics has a net margin of -194.74% compared to Alector's net margin of -850.13%. 4D Molecular Therapeutics' return on equity of -41.33% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

4D Molecular Therapeutics has higher revenue and earnings than Alector. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.60	-$142.93M	-$1.10	N/A
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A

Summary

4D Molecular Therapeutics beats Alector on 12 of the 17 factors compared between the two stocks.

How does Alector compare to Geron?

Alector (NASDAQ:ALEC) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Alector has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Geron has higher revenue and earnings than Alector. Geron is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.60	-$142.93M	-$1.10	N/A
Geron	$183.88M	4.19	-$83.50M	-$0.11	N/A

85.8% of Alector shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 1.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Alector had 1 more articles in the media than Geron. MarketBeat recorded 2 mentions for Alector and 1 mentions for Geron. Alector's average media sentiment score of 0.67 beat Geron's score of 0.51 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alector currently has a consensus target price of $3.63, indicating a potential upside of 100.28%. Geron has a consensus target price of $4.00, indicating a potential upside of 233.33%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Geron has a net margin of -34.17% compared to Alector's net margin of -850.13%. Geron's return on equity of -24.48% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Geron	-34.17%	-24.48%	-10.30%

Summary

Alector and Geron tied by winning 8 of the 16 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$202.10M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-1.65	13.06	275.68	26.04
Price / Sales	14.58	1,374.07	658.29	101.16
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	6.46	16.63	10.93	6.31
Net Income	-$142.93M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-7.18%	-2.99%	-2.00%	-1.66%
1 Month Performance	-27.89%	-10.60%	-6.15%	-4.50%
1 Year Performance	-45.48%	19.44%	7.44%	2.06%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	2.805 of 5 stars	$1.81 -2.7%	$3.63 +100.3%	-42.7%	$202.10M	$13.86M	N/A	103	News Coverage
AVTX Avalo Therapeutics	2.4358 of 5 stars	$15.47 -1.6%	$45.10 +191.5%	+15.3%	$843.06M	$60K	N/A	33
IMMX Immix Biopharma	3.1119 of 5 stars	$10.97 -6.2%	$22.86 +108.4%	+361.0%	$837.01M	N/A	N/A	21	Analyst Forecast
LXRX Lexicon Pharmaceuticals	1.9342 of 5 stars	$1.80 -3.5%	$4.55 +153.5%	+31.9%	$827.62M	$49.80M	N/A	81
FDMT 4D Molecular Therapeutics	2.8468 of 5 stars	$14.47 -1.6%	$28.56 +97.3%	+57.7%	$812.64M	$85.21M	N/A	196	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. AVTX, IMMX, LXRX, FDMT, and GERN

How does Alector compare to Avalo Therapeutics?

Summary

How does Alector compare to Immix Biopharma?

Summary

How does Alector compare to Lexicon Pharmaceuticals?

Summary

How does Alector compare to 4D Molecular Therapeutics?

Summary

How does Alector compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. AVTX, IMMX, LXRX, FDMT, and GERN

How does Alector compare to Avalo Therapeutics?

Is ALEC or AVTX more profitable?

Do analysts recommend ALEC or AVTX?

Which has higher valuation and earnings, ALEC or AVTX?

Do institutionals & insiders have more ownership in ALEC or AVTX?

Which has more volatility and risk, ALEC or AVTX?

Does the media favor ALEC or AVTX?

Summary

How does Alector compare to Immix Biopharma?

Which has more risk and volatility, ALEC or IMMX?

Do analysts prefer ALEC or IMMX?

Is ALEC or IMMX more profitable?

Do insiders and institutionals have more ownership in ALEC or IMMX?

Which has better valuation & earnings, ALEC or IMMX?

Does the media favor ALEC or IMMX?

Summary

How does Alector compare to Lexicon Pharmaceuticals?

Which has better valuation and earnings, ALEC or LXRX?

Which has more risk and volatility, ALEC or LXRX?

Do institutionals and insiders believe in ALEC or LXRX?

Do analysts rate ALEC or LXRX?

Does the media favor ALEC or LXRX?

Is ALEC or LXRX more profitable?

Summary

How does Alector compare to 4D Molecular Therapeutics?

Which has more volatility and risk, ALEC or FDMT?

Does the media favor ALEC or FDMT?

Do insiders and institutionals believe in ALEC or FDMT?

Do analysts recommend ALEC or FDMT?

Is ALEC or FDMT more profitable?

Which has preferable earnings & valuation, ALEC or FDMT?

Summary

How does Alector compare to Geron?

Which has more volatility & risk, ALEC or GERN?

Which has stronger valuation & earnings, ALEC or GERN?

Do insiders & institutionals believe in ALEC or GERN?

Does the media favor ALEC or GERN?

Do analysts recommend ALEC or GERN?

Is ALEC or GERN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools